<DOC>
	<DOCNO>NCT00424281</DOCNO>
	<brief_summary>Patients intensive care unit high risk develop blood clot . Arixtra inhibit blood clot formation bind blood clot factor , Xa . Critical illness , specifically , medication give ICU increase arterial blood pressure ( vasopressor ) may impair absorption drug like Arixtra give subcutaneously . The study measure level Arixtra blood compare subject subject blood pressure medication .</brief_summary>
	<brief_title>Effectiveness Blood Clot Medication With Concomitant Blood Pressure Medication</brief_title>
	<detailed_description>In view high risk venous thrombolism ( VTE ) critically ill patient , essential ICUs develop standardized approach thromboprophylaxis . Several study critical set show low dose unfractionated heparin low molecular weight heparin ( LMWH ) reduce incidence VTE either one recommend valid agent new ACCP consensus guideline . However , even prophylaxis , critically ill patient still develop VTE . Common condition amongst ICU patient generalize edema , poor peripheral perfusion shock state , moderate renal dysfunction , etc. , possible explanation observation . Additionally , use vasoactive drug may also impair peripheral circulation reduce effective level agent use prevention VTE . This prospective clinical trial conduct assess whether impaired peripheral circulation due vasopressor ( blood pressure ) infusion decrease bioavailability ( i.e. , plasma concentration ) subcutaneously administer fondaparinux ( i.e. , vasopressor infusion lower blood plasma concentration fondaparinux ) , thereby reduce prophylactic benefit fondaparinux administration . Fondaparinux ( ArixtraÂ® ) choose anti-thrombotic agent use study unique pharmacological property safety efficacy amongst different medical population . Fondaparinux sodium administer subcutaneous injection rapidly completely absorb ( absolute bioavailability 100 % ) . Following single subcutaneous dose fondaparinux sodium 2.5 mg young male subject , Cmax 0.34 mg free acid/L reach approximately 2 hour . In patient undergoing treatment fondaparinux sodium injection 2.5 mg , daily , peak steady-state plasma concentration , average , 0.39-0.50 mg free acid/L reach approximately 3 hour post-dose . Because fondaparinux react platelet factor IV , thrombocytopenia unwanted side effect .</detailed_description>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>ICU patient 18 , weight 50 kg ICU enrollment eligible . Pregnant woman neuraxial anesthesia , renal liver problem , BMI 40 eligible . Patients 18 , weight less 50 kg , pregnant woman neuraxial anesthesia , renal liver problem , BMI 40 eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Arixtra , fondaparinux , vasopressor , venous thrombolism</keyword>
</DOC>